2021
A plain language summary of results from the ADAURA study: osimertinib after surgery for patients who have early-stage EGFR-mutated non-small cell lung cancer
Wu YL, Tsuboi M, John T, Grohe C, Majem M, Goldman JW, Laktionov K, Kim SW, Kato T, Vu HV, Lu S, Lee KY, Akewanlop C, Yu CJ, de Marinis F, Bonanno L, Domine M, Shepherd FA, Zeng L, Hodge R, Atasoy A, Rukazenkov Y, Herbst RS. A plain language summary of results from the ADAURA study: osimertinib after surgery for patients who have early-stage EGFR-mutated non-small cell lung cancer. Future Oncology 2021, 17: 4827-4835. PMID: 34723634, DOI: 10.2217/fon-2021-0752.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerCell lung cancerClinical studiesADAURA studyLung cancerPost-surgery chemotherapyTypes of NSCLCRisk of tumorsPrevious clinical studiesCentral nervous systemEpidermal growth factor receptorEarly-stage EGFRGrowth factor receptorNCT numberActivity of EGFROsimertinib treatmentNSCLC tumorsSpinal cordTumor removalNSCLCSide effectsNervous systemOsimertinibPatientsSurgeryToward personalized treatment approaches for non-small-cell lung cancer
Wang M, Herbst RS, Boshoff C. Toward personalized treatment approaches for non-small-cell lung cancer. Nature Medicine 2021, 27: 1345-1356. PMID: 34385702, DOI: 10.1038/s41591-021-01450-2.Peer-Reviewed Original ResearchConceptsCell lung cancerLung cancerCombination therapyMaintenance combination therapyRobust predictive biomarkersCancer-related deathPersonalized treatment approachesRational combination therapiesAdvanced NSCLCEarly diseasePredictive biomarkersClinical studiesCurrent treatmentCommon causePatient stratificationTreatment approachesTherapyNSCLCBreakthrough therapiesCancerClinical research areasImmunotherapyVast majorityCurrent understandingFuture role
2018
A comparative clinical study of PF-06439535, a candidate bevacizumab biosimilar, and reference bevacizumab, in patients with advanced non-squamous non-small cell lung cancer.
Socinski M, Von Pawel J, Kasahara K, Bondarenko I, Syrigos K, Vladimirov V, Bryl M, Zereu M, Bair A, Hilton F, Liau K, Herbst R. A comparative clinical study of PF-06439535, a candidate bevacizumab biosimilar, and reference bevacizumab, in patients with advanced non-squamous non-small cell lung cancer. Journal Of Clinical Oncology 2018, 36: 109-109. DOI: 10.1200/jco.2018.36.15_suppl.109.Peer-Reviewed Original Research
2014
New Strategies in Personalized Medicine for Solid Tumors: Molecular Markers and Clinical Trial Designs
Jürgensmeier JM, Eder JP, Herbst RS. New Strategies in Personalized Medicine for Solid Tumors: Molecular Markers and Clinical Trial Designs. Clinical Cancer Research 2014, 20: 4425-4435. PMID: 25183480, PMCID: PMC5369358, DOI: 10.1158/1078-0432.ccr-13-0753.Peer-Reviewed Original ResearchConceptsClinical trialsTumor biologyFuture patient selectionTherapy of patientsOngoing clinical evaluationBroad molecular profilingPromising tumor targetPersonalized medicinePatient selectionPatient populationTreatment recommendationsClinical evaluationTumor boardClinical studiesImmune parametersNovel agentsTumor targetsTreatment approachesSolid tumorsClinical researchPatientsMolecular profilingSpecific markersTumorsTrials
2009
Targeted drug delivery strategies to treat lung metastasis
Bar J, Herbst RS, Onn A. Targeted drug delivery strategies to treat lung metastasis. Expert Opinion On Drug Delivery 2009, 6: 1003-1016. PMID: 19663628, DOI: 10.1517/17425240903167926.Peer-Reviewed Original ResearchConceptsLung metastasesStandard clinical useMetastatic diseaseClinical trialsClinical useMost cancer patientsEarly clinical studiesCancer-specific antibodiesDrug delivery strategiesMain tumorTargeted drug delivery strategiesCancer patientsClinical studiesIntravascular devicesSolid tumorsMetastasisPreclinical developmentVascular fieldTreatmentTherapyTumorsAnticancer toolDiseaseDelivery strategiesTrialsTumor Blood Flow Measured by Perfusion Computed Tomography and 15O-Labeled Water Positron Emission Tomography
Ng CS, Kodama Y, Mullani NA, Barron BJ, Wei W, Herbst RS, Abbruzzese JL, Charnsangavej C. Tumor Blood Flow Measured by Perfusion Computed Tomography and 15O-Labeled Water Positron Emission Tomography. Journal Of Computer Assisted Tomography 2009, 33: 460-465. PMID: 19478644, DOI: 10.1097/rct.0b013e318182d2e0.Peer-Reviewed Original ResearchConceptsWater positron emission tomographyPositron emission tomographyBlood flowEmission tomographyMean blood flow valuesBlood flow estimatesPerfusion Computed TomographyTumor blood flowPairs of examinationsBlood flow valuesMixed regression analysesUse of PCTBlood flow measurementsClinical gold standardIndex tumorClinical studiesComputed tomographySolid tumorsTumorsGold standardBland-AltmanTomographySignificant differencesRegression analysisT-test
2008
Correlation between plasma cytokine/angiogenic factors (C/AF) and signaling pathways activation from baseline tumor biopsy specimens in patients with advanced non small cell lung cancer (NSCLC): Preliminary analysis from the Biomarker-based Approaches of Targeted Therapy for Lung Cancer Elimination (BATTLE) Clinical Study
Tran H, Kim E, Lee J, Herbst R, Liu S, Wistuba I, Yan S, Mao L, Hong W, Heymach J. Correlation between plasma cytokine/angiogenic factors (C/AF) and signaling pathways activation from baseline tumor biopsy specimens in patients with advanced non small cell lung cancer (NSCLC): Preliminary analysis from the Biomarker-based Approaches of Targeted Therapy for Lung Cancer Elimination (BATTLE) Clinical Study. Journal Of Clinical Oncology 2008, 26: 8010-8010. DOI: 10.1200/jco.2008.26.15_suppl.8010.Peer-Reviewed Original Research
2006
Multicenter Open-label Extension Trial of Long-term Treatment with Gefitinib (IRESSA®)
Nakagawa K, Ranson M, Yano S, Tamura T, Saka H, Imamura F, Yokoyama A, Matsui K, Jiang H, Herbst R. Multicenter Open-label Extension Trial of Long-term Treatment with Gefitinib (IRESSA®). Haigan 2006, 46: 345. DOI: 10.2482/haigan.46.345.Peer-Reviewed Original ResearchProgression-free survivalLong-term treatmentNew safety issuesExtension trialOpen-label extension trialSkin-related adverse eventsMedian overall survivalMajority of patientsLong-term safetyGefitinib monotherapyAdvanced NSCLCAdverse eventsOverall survivalParent trialClinical benefitGefitinib treatmentSafety profileClinical trialsClinical studiesPatientsGefitinibIdeal 1TrialsSafety issuesSurvival
2001
Clinical studies of angiogenesis inhibitors: The university of texas md anderson center trial of human endostatin
Herbst R, Lee A, Tran H, Abbruzzese J. Clinical studies of angiogenesis inhibitors: The university of texas md anderson center trial of human endostatin. Current Oncology Reports 2001, 3: 131-140. PMID: 11177745, DOI: 10.1007/s11912-001-0013-8.Peer-Reviewed Original ResearchConceptsPhase I trialI trialClinical studiesHuman endostatinTumor vasculatureSolid tumor malignanciesAnti-angiogenic agentsAnti-angiogenic mechanismAnti-angiogenic compoundsToxic cancer treatmentsAdvanced diseaseBlood vessel supplyCenter trialMinimal diseaseTumor sizeNovel agentsSurrogate endpointsNew agentsSide effectsBiologic mechanismsSingle agentAngiogenesis inhibitorsGrowth-inhibiting moleculesNon-toxic agentsTumor growth